SCHEMBL2188679

SCHEMBL2188679

CC(C)([C@@H]1CCN(c2ncc(C(F)(F)F)c(Cl)n2)C(=O)C1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.42
CACNA1B Q00975 2/20 0.42
NR1I2 O75469 1/20 0.42
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
HSD11B1 P28845 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.35
HCRTR2 O43614 1/20 0.34
RORC P51449 3/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
KDM4E B2RXH2 1/20 0.34
CNR1 P21554 1/20 0.34
CTSS P25774 1/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
HTR6 P50406 1/20 0.34
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2188161 1.00 CYP3A4 (0.42) CYP3A4CACNA1BNR1I2NR1H2NR1H3
SCHEMBL2188500 0.88 CACNA1B (0.45) CYP3A4CACNA1BNR1I2HSD11B1L3MBTL1
SCHEMBL2187285 0.87 CACNA1B (0.47) CYP3A4CACNA1BNR1I2HSD11B1L3MBTL1
SCHEMBL2190203 0.87 CACNA1B (0.47) CYP3A4CACNA1BNR1I2HSD11B1L3MBTL1
SCHEMBL1728002 0.84 CYP3A4 (0.45) CYP3A4CACNA1BNR1I2NR1H2NR1H3
SCHEMBL2187708 0.84 CYP3A4 (0.45) CYP3A4CACNA1BNR1I2NR1H2NR1H3
SCHEMBL2190746 0.84 CYP3A4 (0.45) CYP3A4CACNA1BNR1I2NR1H2NR1H3
SCHEMBL2189669 0.82 CACNA1B (0.49) CYP3A4CACNA1BNR1I2NR1H2NR1H3
SCHEMBL2190814 0.81 ALDH1A1 (0.47) CYP3A4CACNA1BNR1I2HSD11B1L3MBTL1
SCHEMBL2187135 0.81 ALDH1A1 (0.47) CYP3A4CACNA1BNR1I2HSD11B1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US claimed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D CYP3A4 939/4885CACNA1B 23/4885NR1I2 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.